title: Bone neoplasms in F344 rats given teriparatide [rhPTH(1-34)] are dependent on duration of treatment and dose.
abstract: A long-term study was conducted in female F344 rats to determine the relative importance of dose, treatment duration, and age at initiation of treatment on the incidence of teriparatide [rhPTH[1-34)]-induced bone proliferative lesions. Treatment groups consisted of different combinations of dose (0, 5, or 30 microg/kg/d), treatment duration (6, 20, or 24 months) and age at initiation of treatment (2 or 6 months of age). The primary endpoints were the incidence of bone neoplasms and effects on bone mass and structure as evaluated by quantitative computed tomography and histomorphometery. Significant increases in the incidence of bone tumors (osteoma, osteoblastoma, and osteosarcoma) occurred in rats treated with 30 microg/kg for 20 or 24 months. No neoplasms were found when the 5 microg/kg treatment was initiated at 6 months of age and continued for either 6 or 20 months (up to 70% of life span). This treatment regimen defined a "no-effect" dose for neoplasm formation that nevertheless resulted in substantial increases in bone mass. These results demonstrate that treatment duration and administered dose are the most important factors in the teriparatide-induced bone tumors in rats.
authors.affiliation: Lilly Research Laboratories, Greenfield, Indiana, USA. jvahle@lilly.com
authors.forename: John L
authors.initials: JL
authors.lastname: Vahle
authors.forename: Gerald G
authors.initials: GG
authors.lastname: Long
authors.forename: George
authors.initials: G
authors.lastname: Sandusky
authors.forename: Michael
authors.initials: M
authors.lastname: Westmore
authors.forename: Yanfei Linda
authors.initials: YL
authors.lastname: Ma
authors.forename: Masahiko
authors.initials: M
authors.lastname: Sato
mesh_terms: D000375:Aging / Q000502:physiology*; D000818:Animals; D015519:Bone Density / Q000187:drug effects; D001859:Bone Neoplasms / Q000139:chemically induced* / Q000000981:diagnostic imaging / Q000453:epidemiology / Q000473:pathology / Q000662:veterinary; D015197:Carcinogenicity Tests / Q000662:veterinary; D002273:Carcinogens / Q000008:administration & dosage / Q000633:toxicity*; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D015994:Incidence; D008297:Male; D019055:No-Observed-Adverse-Effect Level; D051381:Rats; D011916:Rats, Inbred F344; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000633:toxicity; D012737:Sex Factors; D019379:Teriparatide / Q000008:administration & dosage / Q000633:toxicity*; D013997:Time Factors; D036401:Toxicity Tests, Chronic / Q000662:veterinary; D014463:Ultrasonography
chemical_list: D002273:Carcinogens; D011994:Recombinant Proteins; D019379:Teriparatide